Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTI164 in Children and Young Adults With Autism Spectrum Disorder
NCT07257939Phase 3Not yet recruiting
- Sponsor
- Fenix Innovation Group
- Start
- Sep 2026
- Primary completion
- Jul 2029
- Modality
- PE (Plant Extract)
- Countries
- 1
01
Overview
A Phase 3 trial of NTI164 in Autism Spectrum Disorder (ASD), sponsored by Fenix Innovation Group. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
NTI164
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT07257939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07257939.